Targeting Protein-Protein Interactions: A Promising Avenue of Anti-HIV Drug Discovery
Abstract:In recent years, the number of useful chemical biology information of protein-protein interactions in the HIV life cycle and related inhibitors, is growing rapidly, which makes protein-protein interactions a new investigative area for antiviral drug intervention. This review will summarize recent work in this field, mainly focusing on the utilization of small molecules targeted against a variety of protein-protein interactions that have great therapeutic feasibility for HIV infection, and lastly outline some other important protein-protein interactions with a potential to advance into novel anti- HIV drug targets in future.
Keywords: (ELISA); (Vpr); AIDS; Anti-HIV; Bris-tol-Myers Squibb; CCR5 coreceptor; CD4; CHIBA-3003; CRM1-NES; Dimerization Inhibitors; GAG-TSG101; GP120-CD4; Gag; HAART); HIV; HIV enzymes; HIV therapy; HIV-1 inhibition; LEDGF/p75; MAPPIT; NF-B; PR dimerization inhibitors; Protein-Protein Interactions; RNase H; Rev protein; SAR; SQs; Schiffs base linkage; TEFb; VIF-APOBEC3G; allosteric site; anti-AIDS; capsid protein; cell-based assays; clinical trials; drug design; drug targets; inhibitor; integrase; peptidomimetics; protease; protein-protein interactions; reverse transcriptase
Document Type: Research Article
Publication date: October 1, 2010
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.